Rheumotologitsts’ view on the use of hydroxychloroquine to treat COVID-19
The current pandemic coronavirus disease 2019 (COVID-19) caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) calls urgently for effective therapies. Anti-malarial medicine chloroquine (CQ) and particularly its chemical analogue hydroxychloroquine (HCQ) have been recommended as...
Saved in:
| Main Authors: | Xiaoxuan Sun, Yicheng Ni, Miaojia Zhang |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Taylor & Francis Group
2020-01-01
|
| Series: | Emerging Microbes and Infections |
| Subjects: | |
| Online Access: | https://www.tandfonline.com/doi/10.1080/22221751.2020.1760145 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
CHLOROQUINE AND HYDROXYCHLOROQUINE ARE AVAILABLE TREATMENT OPTIONS TO FIGHT WITH COVID-19
by: Shadia S. Alhamd, et al.
Published: (2020-11-01) -
Hydroxychloroquine – Beyond Malaria: Its Role in Rheumatology and COVID-19 – A Literature Review
by: Adam Jan Ząbek, et al.
Published: (2025-04-01) -
Drug Interactions and Side Effects of Co-Administration of Chloroquine/Hydroxychloroquine and Azithromycin: on the Issue of Rational Pharmacotherapy of Patients with COVID-19 with Antimalarial Drugs
by: O. V. Gaisenok
Published: (2020-07-01) -
Comparative outcomes of COVID-19 in patients with primary Sjögren’s syndrome treated with hydroxychloroquine versus methotrexate: a retrospective cohort study
by: Jih-Jin Tsai, et al.
Published: (2025-12-01) -
Efficacy and safety of hydroxychloroquine for treatment of mild SARS‐CoV‐2 infection and prevention of COVID‐19 severity in pregnant and postpartum women: A randomized, double‐blind, placebo‐controlled trial
by: Raquel González, et al.
Published: (2024-03-01)